Von Eschenbach nomination blocked again

Share this article:
Sen. Charles Grassley (R-Iowa) said he would block Andrew von Eschenbach’s confirmation to head the FDA. As a reason for his opposition, Grassley cited von Eschenbach’s failure to comply with subpoenas issued by the Senate Finance Committee, which has oversight over the FDA. In a letter to outgoing Majority Leader Bill Frist (R-Tenn.), Grassley also mentioned that he and Sen. Max Baucus (D-Mont.) had met with HHS Secretary Mike Leavitt to express their objections. Grassley asked Frist to consult him before “entering into any unanimous consent agreement” on von Eschenbach’s nomination, according to Bloomberg News. The letter didn’t describe the subject of the subpoenas, issued in May for access to documents and an agency employee. Grassley’s represents the third hold on the von Eschenbach nomination by a Republican senator. The other two Republican holds have come from Sens. Jim DeMint of South Carolina and David Vitter of Louisiana. DeMint wants the FDA to withdraw abortion drug RU- 486 from the market, while Vitter is trying to get the Bush administration to allow some prescription drug imports. Before DeMint and Vitter moved to block the nomination, Democrats were holding it up over Barr Pharmaceuticals’ application to sell the Plan B contraceptive without a prescription. The FDA cleared the over-the-counter sales in August for women ages 18 and older.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.